Morphic Holding, Inc.

Equities

MORF

US61775R1059

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
28.07 ^USD	+0.32%		+0.29%	-2.80%

Apr. 25	Morphic Holding, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 19	Morphic Holding Names Simon Cooper as Chief Medical Officer	MT

Morphic Holding, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 03, 2023 at 07:16 am EDT

Morphic Holding, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 36.21 million compared to USD 30.02 million a year ago. Basic loss per share from continuing operations was USD 0.73 compared to USD 0.78 a year ago.
For the nine months, net loss was USD 111.36 million compared to USD 34.66 million a year ago. Basic loss per share from continuing operations was USD 2.65 compared to USD 0.91 a year ago.

Latest news about Morphic Holding, Inc.

Morphic Holding, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Morphic Holding Names Simon Cooper as Chief Medical Officer	Mar. 19	MT
Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer	Mar. 19	CI
Morphic Holding's Full Year 2023 Net Loss Widens, Collaboration Revenue Falls	Feb. 22	MT
Morphic Holding, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
North American Morning Briefing : Stock Futures -2-	Feb. 21	DJ
Transcript : Morphic Holding, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM	Jan. 10
Morphic Ethical Equities Fund Buys Back Shares	Dec. 27	MT
Citigroup Starts Morphic Holding With Buy Rating, $46 Price Target	Dec. 08	MT
RBC Cuts Price Target on Morphic Holding to $76 From $80, Keeps Outperform, Speculative Risk	Nov. 06	MT
Morphic Holding, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
Morphic Holding, Inc. Announces Chief Executive Officer Changes	Nov. 03	CI
Transcript : Morphic Holding, Inc. - Special Call	23-10-12
BMO Capital Lowers Price Target on Morphic to $52 From $106, Maintains Outperform Rating	23-09-28	MT
North American Morning Briefing : Stock Futures Helped by Retreating Bond Yields	23-09-27	DJ
Morphic Holdings Inc. Announces Chief Executive Officer, Praveen Tipirneni Suffered an Emergent Medical Event and Taking Medical Leave of Absence	23-09-26	CI
Morphic Chief Executive to Take Medical Leave of Absence; Shares Slump After Hours	23-09-26	MT
North American Morning Briefing : Yield Surge -2-	23-09-26	DJ
Morphic Holding's 37% Monday Slump Coincides With BTIG Analyst Downgrade, Stifel Share-Price Target Cut of Almost 50%	23-09-25	MT
Stifel Cuts Morphic Holding's Price Target to $33 From $61, Hold Rating Maintained	23-09-25	MT
BTIG Research Downgrades Morphic to Neutral From Buy	23-09-25	MT
Insider Sell: Morphic Holding	23-09-11	MT
North American Morning Briefing : Attention Turns -2-	23-08-10	DJ
Stifel Downgrades Morphic Holding to Hold From Buy, Adjusts Price Target to $61 From $69	23-08-09	MT
Morphic Holding, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI

Chart Morphic Holding, Inc.

Duration

Period

More charts

Company Profile

Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Companyâs Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). It has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - RBC Capital Markets Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

28.07 USD

Average target price

56 USD

Spread / Average Target

+99.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MORPHIC HOLDING, INC.	-2.80%	1.41B
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research